基于常规收集健康医疗数据的上市药品安全性评价研究设计和分析技术专家共识

doi:10.19803/j.1672-8629.2022.01.02

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (1): 7-12.
DOI: 10.19803/j.1672-8629.2022.01.02

• 真实世界数据支持药械监测与评价(一）专栏 • 上一篇下一篇

基于常规收集健康医疗数据的上市药品安全性评价研究设计和分析技术专家共识

王雯^1,2, 刘梅^1,2, 何俏^1,2, 田春华³, 宋海波³, 王涛³, 谭婧^1,2, 任燕^1,2, 高培⁴, 彭晓霞⁵, 温泽淮⁶, 舒啸尘⁷, 邹康^1,2, 沈传勇^3#, 孙鑫^1,2,*

¹四川大学华西医院中国循证医学中心,四川成都 610041;
²国家药品监督管理局海南真实世界数据研究与评价重点实验室,海口海南 570100;
³国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 10022;
⁴北京大学公共卫生学院流行病与卫生统计学系,北京 100191;
⁵国家儿童医学中心,首都医科大学附属北京儿童医院,临床流行病学与循证医学中心,北京 100045;
⁶广东省中医院临床研究方法学重点研究室,广东广州 510120;
⁷苏州大学公共卫生学院流行病与卫生统计学系,江苏苏州 215123

收稿日期:2021-09-30 出版日期:2022-01-15 发布日期:2022-01-20
通讯作者: ^*孙鑫,男,博士,研究员,临床流行病学与循证医学。E-mail：sunx79@hotmail.com。^#为共同通信作者。
作者简介:王雯,女,博士,临床流行病学与循证医学。
基金资助:
国家自然科学基金青年科学基金项目（72104155）; 四川省青年科技创新研究团队（2020JDTD0015）; 中国中医药循证医学中心“业务研究室主任专项”（2020YJSZX-3）; 国家药品监督管理局“上市后药品的安全性监测和评价方法研究项目”（HX-H2003033）

Expert consensus on design and statistical analysis to evaluate drug safety using routinely collected health data

WANG Wen^1,2, LIU Mei^1,2, HE Qiao^1,2, TIAN Chunhua³, SONG Haibo³, WANG Tao³, TAN Jing^1,2, REN Yan^1,2, GAO Pei⁴, PENG Xiaoxia⁵, WEN Zehuai⁶, SHU Xiaochen⁷, ZOU Kang^1,2, SHEN Chuanyong^3#, SUN Xin^1,2,*

¹Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu Sichuan 610041, China;
²NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Haikou Hainan 570100, China;
³Center for Drug Reevaluation, NMPA/NMPA, Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100022, China;
⁴Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing 100191, China;
⁵Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China;
⁶Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou Guangdong 510120, China;
⁷Department of Epidemiology and Biostatistics, School of Public Health, Medical College Soochow University, Suzhou Jiangsu 215123, China

Received:2021-09-30 Online:2022-01-15 Published:2022-01-20

摘要/Abstract

摘要： 作为真实世界数据的重要组成,常规收集的健康医疗数据（RCD）已广泛应用到上市后药品安全性评价。但如何生成高质量的RCD证据支持上市后药品安全性监管决策,在研究设计和分析上还存在挑战。本专家共识通过阐明RCD的定义、应用,并针对研究设计、数据分析提出基于RCD的上市后药品安全性评价基本要求及注意事项,以期促进我国高质量的研究证据的生产及应用。

关键词: 真实世界数据, 药品安全性评价, 常规收集的健康医疗数据

Abstract: As an important source for real world data, routinely collected health data (RCD) have been widely used for drug safety evaluation. However, the production of trustworthy evidence informing drug safety regulatory decision still have substantial challenges, such as inadequate research capacity in design and analysis. In this expert consensus, we introduced the concept and applications of RCD in drug safety evaluation; summarize the issues and proposed recommendations for study design and analysis. We hope this paper may improve the quality of production and use of evidence generating from RCD.

Key words: real world data, drug safety evaluation, routinely collected health data

中图分类号:

R994.11

王雯, 刘梅, 何俏, 田春华, 宋海波, 王涛, 谭婧, 任燕, 高培, 彭晓霞, 温泽淮, 舒啸尘, 邹康, 沈传勇, 孙鑫. 基于常规收集健康医疗数据的上市药品安全性评价研究设计和分析技术专家共识[J]. 中国药物警戒, 2022, 19(1): 7-12.

WANG Wen, LIU Mei, HE Qiao, TIAN Chunhua, SONG Haibo, WANG Tao, TAN Jing, REN Yan, GAO Pei, PENG Xiaoxia, WEN Zehuai, SHU Xiaochen, ZOU Kang, SHEN Chuanyong, SUN Xin. Expert consensus on design and statistical analysis to evaluate drug safety using routinely collected health data[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 7-12.

参考文献

[1] SUN X, TAN J, TANG L, et al.Real world evidence: experience and lessons from China[J]. BMJ, 2018, 360: j5262.
[2] SHERMAN RE, ANDERSON SA, DAL PAN GJ, et al.Real-world evidence- what is it and what can it tell us?[J]. N Engl J Med, 2016, 375(23): 2293-2297.
[3] CORRIGAN-CURAY J, SACKS L, Woodcock J.Real-world evidence and real-world data for evaluating drug safety and effectiveness[J]. JAMA, 2018, 320(9): 867-868.
[4] DAL PAN GJ.Real-world data, advanced analytics, and the evolution of postmarket drug safety surveillance[J]. Clin Pharmacol Ther, 2019, 106(1): 28-30.
[5] XIN S, WEN W, JING T, et al. Producing trustworthy real-world evidence for healthcare practice and policy decisions in China: the initiative to develop an RWE ecosystem and technical guidance[EB/OL]. (2019-10-14)[2021-09-25]. https://press.ispor.org/asia/index.php/2019/10/14/news-across-asia-volume-8-no-3-october-2019/[J].
[6] LANGAN SM, SCHMIDT SA, WING K, et al.The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology(RECORD-PE)[J]. BMJ, 2018, 363: k3532.
[7] HU FY, YE XF, XU JF, et al.Interpretation of the guidance for reporting of pharmacoepidemiology studies conducted using observational routinely collected health data: RECORD-PE Statement[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 144-148.
[8] NIE XL, WU ZH, ZHAO HY, et al.The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) Chinese version-Part I[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2019, 29: 190-198, 212.
[9] NIE XL, WU ZH, ZHAO HY, et al.The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) Chinese version-Part II[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2019, 28(4): 263-272.
[10] BENCHIMOL EI, SMEETH L, GUTTMANN A, et al.The reporting of studies conducted using observational routinely-collected health Data (RECORD) Statement[J]. PLoS Medicine, 2015, 12(10): e1001885.
[11] WANG W, LIU YM, TAN J, et al.Concept and planning of retrospective database study and development of research database[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2018, 18(2): 230-237.
[12] COX E, MARTIN BC, VAN STAA T, et al.Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the international society for pharmacoeconomics and outcomes research good research practices for retrospective database analysis task force report - Part II[J]. Value in Health, 2009, 12(8): 1053-1061.
[13] JOHNSON ML, CROWN W, MARTIN BC, et al.Good research practices for comparative effectiveness research: Analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report - Part III[J]. Value in Health, 2009, 12(8): 1062-1073.
[14] Food and Drug Administration. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data[EB/OL]. (2013-05)[2021-09-25]. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm243537.pdf.
[15] WANG LL, YANG Y, WANG SL.Application of the US FDA sentinel system and enlightenment[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 81-87.
[16] WANG W, GAO P, WU J, et al.Technical guidance for developing research databases using existing health and medical data[J]. Chinese Journal of Evidence-based Medicine(中国循证医学中心), 2019, 19(7): 763-770.
[17] CAI X, YANG F, BIAN Y.Gap analysis on hospitalized health service utilization in floating population covered by different medical insurances — case study from Jiangsu province, China[J]. Int J Equity Health, 2019, 18(1): 84.
[18] WANG W, TAN J, YU C, et al.Explore on safety evaluation mode based on electronic medical records in Chinese[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 134-138.
[19] CHEN ZJ, YAN YJ, SHEN H, et al.MiR-192 is overexpressed and promotes cell proliferation in prostate cancer[J]. Med Princ Pract, 2019, 28(2): 124-132.
[20] BERGER ML, SOX H, WILLKE RJ, et al.Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special task force on real-world evidence in health care decision making[J]. Value in Health, 2017, 20(8): 1003-1008.
[21] ZENG S, MA J, YANG Y, et al Spatial assessment of farmland soil pollution and its potential human health risks in China[J]. Sci Total Environ, 2019, 687: 642-653.
[22] SUISSA S.Immortal time bias in pharmaco-epidemiology[J]. Am J Epidemiol, 2008, 167(4): 492-499.
[23] GUO XB, ZHENG WX, ZENG AC, et al.Forest fire management in the United States[J]. Ying Yong Sheng Tai Xue Bao, 2019, 30(12): 4361-4368.
[24] CHUBAK J, POCOBELLI G, Weiss NS.Tradeoffs between accuracy measures for electronic health care data algorithms[J]. J Clin Epidemiol, 2012, 65(3): 343-349.
[25] KONG AP, LAW SP.Cantonese aphasiabank: an annotated database of spoken discourse and co-verbal gestures by healthy and language-impaired native Cantonese speakers[J]. Behav Res Methods, 2019, 51(3): 1131-1144.

基于常规收集健康医疗数据的上市药品安全性评价研究设计和分析技术专家共识

Expert consensus on design and statistical analysis to evaluate drug safety using routinely collected health data

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

[1]	赵燕, 刘文博, 赵一飞, 李栋, 郑立佳, 宋雅娜, 赵玉娟, 董放. 患者登记研究应用于医疗器械监管科学的实践研究与思考[J]. 中国药物警戒, 2023, 20(4): 423-427.
[2]	吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089.
[3]	滕颖影, 李柴全, 胥洋, 唐迅, 高培. 真实世界数据在医疗器械上市后监测中的应用进展[J]. 中国药物警戒, 2022, 19(3): 233-238.
[4]	李玲, 刘艳梅, 谭婧, 王雯, 姚明宏, 马玉, 罗小超, 廖星, 刘岩, 宋海波, 温泽淮, 孙鑫. 基于真实世界数据的中成药安全性评价模式构建[J]. 中国药物警戒, 2022, 19(1): 18-22.
[5]	谭婧, 刘春容, 黄诗尧, 高培, 王杨, 李晨, 贺勇, 袁洪, 王雯, 李玲, 熊益权, 任燕, 姚明宏, 赵燕, 董放, 沈传勇, 孙鑫. 基于真实世界数据的高风险植入类无源医疗器械上市后风险监测技术专家共识[J]. 中国药物警戒, 2022, 19(1): 13-17.
[6]	刘玉强, 乔瑞, 卓琳, 孟若谷, 孙凤, 詹思延. 真实世界数据在上市后药品安全性研究中的伦理风险[J]. 中国药物警戒, 2021, 18(7): 628-631.
[7]	乔瑞, 刘玉强, 卓琳, 孟若谷, 孙凤, 詹思延. 真实世界数据在上市后药品安全性监测和评价中的适用范围[J]. 中国药物警戒, 2021, 18(7): 620-623.
[8]	薛雪, 金信妍, 鲁春丽, 戴宁, 刘建平. 真实世界研究设计在上市后药品安全性评价的应用[J]. 中国药物警戒, 2021, 18(11): 1025-1028.
[9]	李蒙, 胡豪, 吴霭琳. 大数据在药物警戒中的应用研究进展[J]. 中国药物警戒, 2020, 17(5): 311-314.
[10]	王雯, 谭婧, 于川, 刘艳梅, 吴桂芝, 熊玮仪, 董铎, 孙鑫. 基于中国医院电子病历数据的药品安全性评价模式探索[J]. 中国药物警戒, 2019, 16(3): 134-138.